litlas
Log inCreate account

Mitchell P. Fink

Active 1984–2014

95
Papers
29,969
Citations
84
h-index
95
i10-index

Citations

Citations per year for Mitchell P. Fink1936: 1 citations1986: 3 citations1987: 1 citations1988: 3 citations1989: 10 citations1990: 9 citations1991: 22 citations1992: 50 citations1993: 53 citations1994: 48 citations1995: 60 citations1996: 83 citations1997: 59 citations1998: 87 citations1999: 60 citations2000: 82 citations2001: 74 citations2002: 85 citations2003: 187 citations2004: 240 citations2005: 286 citations2006: 307 citations2007: 382 citations2008: 426 citations2009: 388 citations2010: 390 citations2011: 298 citations2012: 260 citations2013: 297 citations2014: 291 citations2015: 243 citations2016: 252 citations2017: 222 citations2018: 180 citations2019: 668 citations2020: 540 citations2021: 439 citations2022: 312 citations2023: 202 citations2024: 288 citations2025: 136 citations2026: 7 citations1937–1985: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,788 citing papers, 28.6% of this breakdownChina: 927 citing papers, 9.5% of this breakdownUnited Kingdom: 531 citing papers, 5.5% of this breakdownGermany: 471 citing papers, 4.8% of this breakdownCanada: 399 citing papers, 4.1% of this breakdownFrance: 371 citing papers, 3.8% of this breakdownItaly: 331 citing papers, 3.4% of this breakdownNetherlands: 306 citing papers, 3.1% of this breakdownJapan: 278 citing papers, 2.9% of this breakdownAustralia: 271 citing papers, 2.8% of this breakdownSpain: 251 citing papers, 2.6% of this breakdownBelgium: 205 citing papers, 2.1% of this breakdown
0%28.6%Other 26.8%

Institutions

Fields

  • Medicine58.7%
  • Biochemistry, Genetics and Molecular Biology20.5%
  • Immunology and Microbiology9.7%
  • Neuroscience4%
  • Nursing1.7%
  • Pharmacology, Toxicology and Pharmaceutics1%
  • Other4.4%

Topics

  • Sepsis Diagnosis and Treatment11.8%
  • Immune Response and Inflammation6.5%
  • Advanced Glycation End Products research3%
  • Nosocomial Infections in ICU2.5%
  • Intensive Care Unit Cognitive Disorders2.1%
  • Trauma, Hemostasis, Coagulopathy, Resuscitation2%
  • Other72.1%

Coauthors

All papers

Open in search
  1. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

    Authors: Mitchell M. Levy, Mitchell P. Fink, John C. Marshall, Edward Abraham, Derek C. Angus, Deborah Cook, Jonathan Cohen, Steven M. Opal, Jean‐Louis Vincent, Graham Ramsay - Critical Care Medicine 2003 cited by 6,025

  2. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

    Authors: for the International Sepsis Definitions Conference, Mitchell M. Levy, Mitchell P. Fink, John C. Marshall, Edward Abraham, Derek C. Angus, Deborah Cook, Jonathan Cohen, Steven M. Opal, Jean‐Louis Vincent, Graham Ramsay - Intensive Care Medicine 2003 cited by 2,889

  3. Targeting Mitochondria

    Authors: Adam T. Hoye, Jennifer E. Davoren, Peter Wipf, Mitchell P. Fink, Valerian E. Kagan - Accounts of Chemical Research 2008 cited by 634

  4. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion

    Authors: Allan Tsung, Rohit Sahai, Hiroyuki Tanaka, Atsunori Nakao, Mitchell P. Fink, Michael T. Lotze, Huan Yang, Jianhua Li, Kevin J. Tracey, David A. Geller, Timothy R. Billiar - The Journal of Experimental Medicine 2005 cited by 1,102

  5. Animal models of sepsis

    Authors: Mitchell P. Fink - Virulence 2013 cited by 381

  6. Reversing established sepsis with antagonists of endogenous high-mobility group box 1

    Authors: Huan Yang, Mahendar Ochani, Jianhua Li, Xiaoling Qiang, Mahira Tanovic, Helena Erlandsson Harris, Srinivas M. Susarla, Luis Ulloa, Hong Wang, Robert DiRaimo, Christopher J. Czura, Haichao Wang, Jesse Roth, H. Shaw Warren, Mitchell P. Fink, Matthew J. Fenton, Ulf Andersson, Kevin J. Tracey - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 1,127

  7. Strategies to improve drug development for sepsis

    Authors: Mitchell P. Fink, H. Shaw Warren - Nature Reviews Drug Discovery 2014 cited by 246

  8. Structural Basis for the Proinflammatory Cytokine Activity of High Mobility Group Box 1

    Authors: Jianhua Li, Riikka Kokkola, Siamak Tabibzadeh, Runkuan Yang, Mahendar Ochani, Xiaoling Qiang, Helena Erlandsson Harris, Christopher J. Czura, Haichao Wang, Luis Ulloa, Hong Wang, H. Shaw Warren, Lyle L. Moldawer, Mitchell P. Fink, Ulf Andersson, Kevin J. Tracey, Huan Yang - Molecular Medicine 2003 cited by 360

  9. Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicity

    Authors: Runkuan Yang, Keita Miki, Xin He, Meaghan E. Killeen, Mitchell P. Fink - Critical Care 2009 cited by 138

  10. The CRIT Study: Anemia and blood transfusion in the critically ill—Current clinical practice in the United States*

    Authors: Howard L. Corwin, Andrew Gettinger, Ronald G. Pearl, Mitchell P. Fink, Mitchell M. Levy, Edward Abraham, Neil R. MacIntyre, M. Michael Shabot, Mei Sheng Duh, Marc J. Shapiro - Critical Care Medicine 2004 cited by 1,350

  11. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.

    Authors: Howard L. Corwin, Andrew Gettinger, Ronald G. Pearl, Mitchell P. Fink, Mitchell M. Levy, Marc J. Shapiro, Michael J. Corwin, Theodore Colton - 2002 cited by 498

  12. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice

    Authors: Penny L. Sappington, Runkuan Yang, Huan Yang, Kevin J. Tracey, Russell L. Delude, Mitchell P. Fink - Gastroenterology 2002 cited by 320

  13. Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin

    Authors: Elizabeth Ziegler, Charles J. Fisher, Charles L. Sprung, Richard Straube, Jerald Sadoff, Garrett E. Foulke, Cornelis H. Wortel, Mitchell P. Fink, R. Phillip Dellinger, Nelson N.H. Teng, I. Elaine Allen, Harvey J. Berger, Genell L. Knatterud, Albert F. LoBuglio, Craig R. Smith, the HA-1A Sepsis Study Group - New England Journal of Medicine 1991 cited by 1,629

  14. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness

    Authors: Mitchell P. Fink - Current Opinion in Critical Care 2003 cited by 222

  15. IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice

    Authors: Runkuan Yang, Xiaonan Han, Takashi Uchiyama, Simon K. Watkins, Arino Yaguchi, Russell L. Delude, Mitchell P. Fink - American Journal of Physiology-Gastrointestinal and Liver Physiology 2003 cited by 186

  16. Evidence That Glutathione Depletion Is a Mechanism Responsible for the Anti-Inflammatory Effects of Ethyl Pyruvate in Cultured Lipopolysaccharide-Stimulated RAW 264.7 Cells

    Authors: Mingchen Song, John A. Kellum, Hoda Kaldas, Mitchell P. Fink - Journal of Pharmacology and Experimental Therapeutics 2004 cited by 128

  17. Laboratory models of sepsis and septic shock

    Authors: Mitchell P. Fink, Stephen O. Heard - Journal of Surgical Research 1990 cited by 538

  18. Bench-to-bedside review: Cytopathic hypoxia.

    Authors: Mitchell P. Fink - Critical Care 2002 cited by 382

  19. Epithelial Barrier Dysfunction: A Unifying Theme to Explain the Pathogenesis of Multiple Organ Dysfunction at the Cellular Level

    Authors: Mitchell P. Fink, Russell L. Delude - Critical Care Clinics 2005 cited by 278

  20. Red blood cell physiology in critical illness

    Authors: Marion Scharte, Mitchell P. Fink - Critical Care Medicine 2003 cited by 198

  21. Nitro-fatty Acid Reaction with Glutathione and Cysteine

    Authors: Laura M.S. Baker, Paul R.S. Baker, Franca Golin-Bisello, Francisco J. Schöpfer, Mitchell P. Fink, Steven R. Woodcock, Bruce P. Branchaud, Rafael Radí, Bruce Α. Freeman - Journal of Biological Chemistry 2007 cited by 196

  22. Treatment With a Novel Hemigramicidin-TEMPO Conjugate Prolongs Survival in a Rat Model of Lethal Hemorrhagic Shock

    Authors: Carlos Macías, Jeffrey W Chiao, Jingbo Xiao, Devinder Arora, Yulia Y. Tyurina, Russell L. Delude, Peter Wipf, Valerian E. Kagan, Mitchell P. Fink - Annals of Surgery 2007 cited by 88

  23. Systemic inflammation and remote organ injury following trauma require HMGB1

    Authors: Ryan M. Levy, Kevin P. Mollen, José M. Prince, David Kaczorowski, Raghuveer Vallabhaneni, Shiguang Liu, Kevin J. Tracey, Michael T. Lotze, David J. Hackam, Mitchell P. Fink, Yoram Vodovotz, Timothy R. Billiar - American Journal of Physiology-Regulatory, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2007 cited by 227

  24. Anti-HMGB1 Neutralizing Antibody Ameliorates Gut Barrier Dysfunction and Improves Survival after Hemorrhagic Shock

    Authors: Runkuan Yang, Tomoyuki Harada, Kevin P. Mollen, José M. Prince, Ryan M. Levy, Joshua A. Englert, Margot Gallowitsch‐Puerta, Lihong Yang, Huan Yang, Kevin J. Tracey, Brian G. Harbrecht, Timothy R. Billiar, Mitchell P. Fink - Molecular Medicine 2006 cited by 224